Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: 2 - The Real Truth

Johnson & Johnson Is a Resilient Blue-Chip Stock and It Just Hit New All-Time Highs

Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs. The stock maintains a 100% “Buy” technical opinion from Barchart. Analyst sentiment is mixed. JNJ has many “Strong Buy” opinions, but some analysts consider JNJ overvalued. Today’s...

Barchart

What Are Wall Street Analysts' Target Price for Johnson & Johnson Stock?

Although Johnson & Johnson has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

1 Dividend King to Buy and Hold Through Any Market

In uncertain markets, reliable income matters more than ever. This Dividend King offers exactly that.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Johnson & Johnson Quietly Triggers a Trend Following Buy Signal

Johnson & Johnson is poised to advance in H2 2026 as growth, cash flow, and capital returns drive bullish analysts and institutional sentiment.

MarketBeat

2 Rock-Solid Dividend Stocks to Buy for Steady Passive Income

These two income stocks can weather every cycle.

Barchart

What to Expect From Johnson & Johnson’s Next Quarterly Earnings Report

Investor interest is building ahead of Johnson & Johnson’s Q4 earnings, backed by positive analyst sentiment.

Barchart

5 Healthcare Names to Watch as Sector Rotation Is in Full Swing

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

3 Highest-Yielding Dividend Kings To Buy, Hold, and Forget

Discover three Dividend Kings built for buy-and-forget wealth. These stable giants may quietly deliver income and growth for decades.

Barchart

Is Johnson & Johnson Stock Outperforming the S&P 500?

Johnson & Johnson has outpaced the S&P 500 over the past year, and analysts remain optimistic about the healthcare stock's growth potential ahead.

Barchart

What's Going On With Johnson & Johnson Stock On Wednesday?

Johnson Johnson (NYSE:JNJ) stock has surged almost 42.9% in the year to date, approximately 35% in 6 months, and 8.6% in one month.

Benzinga

3 Smart Defensive Stocks for an Uneasy Market

Recession risks persist despite record market highs. Here are three defensive stocks—including PG, JNJ, and the DIA ETF—that can help protect your portfolio

MarketBeat

FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression

The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson Johnson’s (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer.

Benzinga

Johnson & Johnson Stock: Is Wall Street Bullish or Bearish?

Johnson & Johnson has delivered a standout performance in 2025, outperforming both the broader market and the healthcare sector. Analysts continue to be fairly bullish on the stock’s trajectory.

Barchart

Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations

Patience and a tolerance for risk may be necessary, but these Hold stocks could eventually see big gains, according to analysts.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Ken Paxton Alleges Johnson & Johnson Misled Mothers On Tylenol Safety

Texas Attorney General Ken Paxton has filed a lawsuit against Johnson Johnson (NYSE:JNJ) and Kenvue Inc (NYSE:KVUE), accusing the companies of misleading pregnant women about the safety of Tylenol despite evidence suggesting its active ingredient, acetaminophen, may increase the risk of autism and attention disorders in children.

Benzinga

Johnson & Johnson Reports Strong Phase 3 Results For Multiple Myeloma Therapy

On Thursday, Johnson Johnson (NYSE:JNJ) announced positive topline results from a recent study.

Benzinga

Johnson & Johnson, Kenvue Named In First Ever UK Legal Action Over Talc Cancer Claims

Thousands of claimants in the U.K. are suing Johnson Johnson (NYSE:JNJ), accusing the healthcare giant of knowingly selling asbestos-contaminated talcum powder that allegedly caused cancer in consumers. The case, involving roughly 3,000 individuals, is one of the largest product liability claims of its kind to reach the High Court in…

Benzinga

Johnson & Johnson Reportedly Faces Major UK Lawsuit Over Baby Powder Cancer Risks

A legal claim involving 3,000 people has been reportedly filed against Johnson Johnson (NYSE:JNJ) in the U.K., alleging that the company knowingly sold asbestos-contaminated baby powder.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst

On Tuesday, Johnson Johnson (NYSE:JNJ) reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.

MarketBeat

Johnson & Johnson Stock Can Keep Rising as Strategy Pays Off

Johnson & Johnson (NYSE: JNJ) beat Q3 estimates, raised revenue guidance, and plans an orthopedics spin-off—analysts see up to 50% upside for JNJ stock.

Benzinga

Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch

Health care giant Johnson Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter financial results are reported before market open Tuesday.

Benzinga

FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy

The Food and Drug Administration (FDA) has updated safety labeling for Johnson Johnson's (NYSE:JNJ) Carvykti after receiving reports of immune effector cell-associated enterocolitis (IEC-EC)—a rare but serious complication seen in both clinical trials and postmarketing data.

Barchart

5 Dividend Kings For Generations Of Passive Income

These are five Dividend Kings, companies with 50+ years of dividend increases, covering recent developments, dividend safety, and valuation, so you can identify candidates for durable income that fit your goals.

Benzinga

Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Johnson Johnson (NYSE:JNJ) will release earnings results for the third quarter, before the opening bell on Tuesday, Oct. 14.

MarketBeat

Why AbbVie and Johnson & Johnson Could Outperform Pfizer

Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.